First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis

Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Roemmler-Zehrer J, Lampl M, Helget U, Gomez NN (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 123-123

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Celgene GmbH DE Germany (DE) licca Klinik für operative Medizin DE Germany (DE)

How to cite

APA:

Mrowietz, U., Ertner, K., Sticherling, M., Grosse, V., Popp, G., Roemmler-Zehrer, J.,... Gomez, N.N. (2019). First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 123-123). HOBOKEN: WILEY.

MLA:

Mrowietz, U., et al. "First real-world insights on benefit of apremilast treatment in patients with moderate to severe psoriasis after switching from fumaric acid esters from the APART Study - an interim analysis." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2019. 123-123.

BibTeX: Download